Pharmacogenomics Clinical Specialist Mayo Clinic Phoenix , Arizona, United States
Adrijana Kekic, PharmD: No financial relationships to disclose
Treatment of psychiatric disorders such as depression and anxiety often follows a trial-and-error process. Increasing evidence has shown that pharmacogenomics (PGx) has the potential to improve drug selection by personalizing treatment based on a patient’s genetic profile. Attend this session to learn which drug classes have the most evidence related to the impact of PGx and practical considerations for using PGx in psychiatric practice.
Identify genetic polymorphisms associated with psychiatric drug response.
Discuss clinical practice guidelines available to inform psychiatric pharmacotherapy adjustment based on pharmacogenetic test results.
Discover barriers and solutions to implementation of pharmacogenetic testing into psychiatric clinical pharmacy practice.